查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604744

金诺芬市场：依形式、适应症分类 - 2025-2030 年全球预测

Auranofin Market by Form (Capsule, Tablet), Indication (Seronegative Rheumatoid Arthritis, Seropositive Rheumatoid Arthritis) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年金诺芬市值为2.092亿美元，预计到2024年将达到2.1899亿美元，复合年增长率为4.81%，到2030年将达到2.9085亿美元。

金诺芬主要被认为是一种抗风湿药，可用于治疗类风湿性关节炎。除了这一主要用途之外，研究还表明其在多种自体免疫疾病和作为抗寄生虫药物中的潜在用途，证明了其在多个治疗领域的多功能性。对金诺芬的需求是由于在典型治疗无法产生预期效果或表现出严重副作用的情况下需要有效的治疗方法，并且它在利基医疗条件下的使用强调了未来的价值。由于其低毒性和口服生物有效性利用度，金诺芬的应用范围正在扩大，这为患者提供了更大的便利，并比注射剂具有竞争优势。最终用途主要是在製药领域，随着安全性和有效性研究的进展，有可能成为动物用药品。

主要市场统计
基准年[2023] 2.092 亿美元
预计年份 [2024] 21899万美元
预测年份 [2030] 29085万美元
复合年增长率（%） 4.81%

市场洞察表明，对具有良好治疗效果的金基化合物的需求不断增长，其中金诺芬处于领先地位。影响成长的关键因素包括自体免疫疾病的增加以及对癌症和神经退化性疾病重新利用的持续探索。精准医疗的出现和金诺芬联合治疗的探索可以释放巨大的市场潜力，并为扩张和利润提供坚实的途径。然而，与金基药物相关的严格监管路径、潜在副作用和高成本等限制因素普遍存在，这可能会阻碍广泛采用和市场进入。

为了利用新的商机，需要进行技术创新，重点是提高金诺芬的生物有效性，减少副作用，并将其应用于罕见和难以治疗的疾病。市场竞争是创新主导的，注重研发以维持和扩大市场占有率。与研究机构的策略联盟和临床试验投资可以有效应对现有挑战并扩大成长前景。识别与治疗领域（尤其是慢性病）相关的未满足需求，是利用未满足关键字的广泛效用的绝佳机会，最终推动业务成长和市场渗透。

市场动态：揭示快速发展的金诺芬市场的关键市场洞察

金诺芬市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 类风湿性关节炎盛行率上升，需要替代治疗
    • 寄生虫感染、某些癌症、金诺芬作为抗病毒药物的潜力
    • 政府和非政府资助慢性病和癌症研究
  • 市场限制因素
    • 与金诺芬相关的副作用
  • 市场机会
    • 探索金诺芬在新治疗应用的有效性
    • 製药公司与研究机构的合作
  • 市场挑战
    • 复杂的监管环境和高昂的临床试验成本

波特的五力：驾驭金诺芬市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解金诺芬市场的外部影响

外部宏观环境因素在塑造金诺芬市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解金诺芬市场的竞争状况

对金诺芬市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵金诺芬市场供应商的绩效评估

FPNV 定位矩阵是评估 Auranofin 市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製金诺芬市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，金诺芬市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 类风湿性关节炎盛行率上升以及对替代治疗的需求
      • 金诺芬具有对抗寄生虫感染疾病、某些癌症和抗病毒药物的潜在作用。
      • 政府和非政府资助慢性病和癌症研究
    • 抑制因素
      • 与金诺芬相关的副作用
    • 机会
      • 探索金诺芬在新治疗应用的有效性
      • 製药公司与研究机构的合作
    • 任务
      • 复杂的监管环境和高成本
  • 市场区隔分析
    • 形式：金诺芬胶囊的相容性，可将活性药物输送到全身并确保均匀分布
    • 适应症：由于发炎涉及细胞机制，金诺芬被推荐用于治疗血清阳性 RA。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 金诺芬市场：依形式

  • 胶囊
  • 锭剂

第七章 金诺芬市场依适应症分类

  • 血清类风湿性关节炎类风湿性关节炎
  • 血清类风湿性关节炎类风湿性关节炎

第八章 金诺芬美洲市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章 亚太地区金诺芬市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲金诺芬市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 关节炎基金会投资 110 万美元用于顽固性类风湿性关节炎研究
  • 战略分析和建议

公司名单

  • Chugai Pharmaceutical Co Ltd
  • LGM Pharma
  • Prometheus Laboratories Inc.
  • Sebela Pharmaceuticals Inc.
  • Taj Pharmaceuticals Limited
  • Xediton Pharmaceuticals
Product Code: MRR-F97DD5A7D98B

The Auranofin Market was valued at USD 209.20 million in 2023, expected to reach USD 218.99 million in 2024, and is projected to grow at a CAGR of 4.81%, to USD 290.85 million by 2030.

Auranofin is primarily recognized as an anti-rheumatic agent for its utility in the treatment of rheumatoid arthritis. Its scope extends beyond this primary application, as research suggests potential usage in addressing various autoimmune diseases and as an anti-parasitic agent, demonstrating its versatility in multiple therapeutic areas. The necessity for Auranofin is driven by the need for effective therapies in conditions where typical treatments either haven't delivered desired outcomes or present severe side effects, emphasizing its prospective value in niche medical conditions. The application scope of Auranofin is expanding, propelled by its low toxicity profile and oral bioavailability, which makes it convenient for patients and offers a competitive edge over injectable counterparts. End-use primarily involves the pharmaceutical sector and possibly veterinary medicine as research into safety and efficacy continues.

KEY MARKET STATISTICS
Base Year [2023] USD 209.20 million
Estimated Year [2024] USD 218.99 million
Forecast Year [2030] USD 290.85 million
CAGR (%) 4.81%

Market insights reveal a growing demand for gold-based compounds due to their promising therapeutic profiles, with Auranofin leading as a frontrunner. Key factors influencing its growth include increased autoimmune disease prevalence and ongoing research into repurposing for cancer and neurodegenerative diseases. The advent of precision medicine and the exploration of Auranofin in combination therapies could unlock significant market potentials, providing robust avenues for expansion and profit. However, predominant limitations include stringent regulatory paths, potential adverse effects, and the high costs associated with gold-based drugs, which may impede widespread adoption and market accessibility.

To capitalize on emerging opportunities, innovation should focus on enhancing Auranofin's bioavailability, reducing side effects, and exploring its use in rare and difficult-to-treat diseases. The market's nature is competitive and innovation-driven, with a strong emphasis on research and development to maintain and grow market share. Strategic collaborations with research institutions and investments in clinical trials could effectively address existing challenges and amplify growth prospects. Identifying unmet needs in therapeutic areas, particularly those associated with chronic diseases, represents an excellent opportunity for leveraging Auranofin's broad spectrum utility, ultimately driving business growth and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Auranofin Market

The Auranofin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of rheumatoid arthritis and the need for alternative treatments
    • Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
    • Governmental and non-governmental funding for chronic diseases and cancer research
  • Market Restraints
    • Side effects associated with Auranofin
  • Market Opportunities
    • Exploring auranofin's efficacy in new therapeutic applications
    • Partnerships between pharmaceutical companies and research institutions
  • Market Challenges
    • Complex regulatory landscape and the high cost of clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the Auranofin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Auranofin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Auranofin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Auranofin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Auranofin Market

A detailed market share analysis in the Auranofin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Auranofin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Auranofin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Auranofin Market

A strategic analysis of the Auranofin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Auranofin Market, highlighting leading vendors and their innovative profiles. These include Chugai Pharmaceutical Co Ltd, LGM Pharma, Prometheus Laboratories Inc., Sebela Pharmaceuticals Inc., Taj Pharmaceuticals Limited, and Xediton Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Auranofin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Capsule and Tablet.
  • Based on Indication, market is studied across Seronegative Rheumatoid Arthritis and Seropositive Rheumatoid Arthritis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of rheumatoid arthritis and the need for alternative treatments
      • 5.1.1.2. Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
      • 5.1.1.3. Governmental and non-governmental funding for chronic diseases and cancer research
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with Auranofin
    • 5.1.3. Opportunities
      • 5.1.3.1. Exploring auranofin's efficacy in new therapeutic applications
      • 5.1.3.2. Partnerships between pharmaceutical companies and research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and the high cost of clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
    • 5.2.2. Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Auranofin Market, by Form

  • 6.1. Introduction
  • 6.2. Capsule
  • 6.3. Tablet

7. Auranofin Market, by Indication

  • 7.1. Introduction
  • 7.2. Seronegative Rheumatoid Arthritis
  • 7.3. Seropositive Rheumatoid Arthritis

8. Americas Auranofin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Auranofin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Auranofin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Chugai Pharmaceutical Co Ltd
  • 2. LGM Pharma
  • 3. Prometheus Laboratories Inc.
  • 4. Sebela Pharmaceuticals Inc.
  • 5. Taj Pharmaceuticals Limited
  • 6. Xediton Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. AURANOFIN MARKET RESEARCH PROCESS
  • FIGURE 2. AURANOFIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AURANOFIN MARKET DYNAMICS
  • TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023